Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma
← catalyst calendarNCT06830759 · readout ≤ 1,868 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →. With Genmab.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
700estimated
Sites
73
Countries
Argentina, Australia, Austria +10
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-28 | actual | When the study began enrolling |
| Primary completion | Sep 2031 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2031 | estimated | The whole study's end, after follow-up |
| First posted | 2025-02-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Diffuse Large B-cell Lymphoma
- Follicular Lymphoma
Primary outcome
what the primary-completion date above is the date OFPercentage of Participants Achieving Overall Response (OR)
measured Up to approximately 3 years
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed